Forty hospitals report 3,500 deaths avoided and improvements in four significant measures, including early elective deliveries
Anthem Blue Cross and several other industry stakeholders collaborating in California’s Patient Safety First initiative have saved more than $63 million in three years. According to participants, more than 3,500 deaths were also avoided.
The group specifically targeted hospital-acquired infections and early elective deliveries at for-profit and not-for-profit facilities. A data sharing aspect and peer-to-peer learning system helped the clinical teams deliver improved care.
Results indicate:
To encourage results, Anthem aligned its quality incentive program criteria for providers with the measures for the safety initiative. Standardized measures were tracked and reported on a quarterly basis.
While 180 hospitals participate, 40 were able to report data consistently throughout the program measurement period.
Improving inpatient care is critical today as hospitals create methods to reduce readmissions for Medicare patients. Last week, Medicare indicated that it will penalize 2,225 hospitals based on insufficient improvement in readmission rates. Total penalties amount to $227 million-often less than a 1% pay reduction for the hospitals involved.
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen